



**Contacts:**

Chris Martin

Vice President, Public Relations

[CMartin@DavidJamesGroup.com](mailto:CMartin@DavidJamesGroup.com) | 630-670-2745

Becky Bunn, MSc

IASLC Project Specialist

[Becky.Bunn@IASLC.org](mailto:Becky.Bunn@IASLC.org) | 720-254-9509

**New Haven Medical Oncologist and Professor to be Honored for Lifetime Scientific Achievement**

*The International Association for the Study of Lung Cancer to Present Paul A. Bunn, Jr. Scientific Award to Roy S. Herbst*

DENVER – Professor Roy S. Herbst, MD, PhD, Yale University, New Haven, will be recognized by The International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 17<sup>th</sup> World Conference on Lung Cancer (WCLC) in Vienna, Austria. Dr. Herbst will accept the Paul A. Bunn, Jr. Scientific Award, honoring his lifetime achievement in scientific contributions to thoracic cancer research.

Dr. Herbst is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at the Yale Cancer Center (YCC) and Yale School of Medicine in New Haven, Conn. Dr. Herbst has worked tirelessly over the past several decades to bring novel targeted agents to clinical trials and ultimately US FDA approval, leading clinical trials to test these agents in advanced stage NSCLC and other cancers. Dr. Herbst's clinical research has and continues to propel the field forward in new and unprecedented ways, with novel strategies to extend patient survival and enhance quality of life through increasingly more sophisticated trial designs and therapeutic agents.

“Dr. Herbst has committed his entire career to advancements in lung cancer research,” said Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine, and CEO of the IASLC. “The IASLC is very proud to honor Dr. Herbst for his very significant contributions, which already have helped many lung cancer patients. He has made a tremendous impact across the globe and we are confident his quality work will continue to be crucial in the fight against lung cancer.”

One of Dr. Herbst's most significant accomplishments has been the progress he has made on promoting individualized, biopsy-driven therapy. As the co-chair of the Lung Master Protocol (Lung MAP) Steering Committee and co-principal investigator of the Lung MAP clinical trial, he has worked on the design and implementation of this clinical trial (open at more than 600 sites in the United States and Canada), which has the potential to further advance the treatment of lung cancers and has drawn formidable interest worldwide. At Yale, he is the principal investigator of a five-year NCI SPORE in Lung Cancer award as well as an American Association of Cancer Research (AACR)/Stand Up to Cancer Dream Team grant.



[www.iaslc.org](http://www.iaslc.org)

Most recently, Dr. Herbst's group has made significant breakthroughs in the area of immunotherapy. The research from his group and from others aided in the decision of the US FDA to approve atezolizumab and pembrolizumab for NSCLC in October 2015.

Dr. Herbst received his bachelor's and master's degrees from Yale University, then earned his MD from Cornell University Medical College and his PhD in molecular cell biology from Rockefeller University in New York. Dr. Herbst also holds a master's degree in clinical translational research from Harvard University in Cambridge, USA.

Dr. Herbst will be honored on Dec. 4, 2016 at the Opening Plenary Session at the IASLC 17<sup>th</sup> WCLC in Vienna, Austria. The IASLC WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 6,000 researchers, physicians, and specialists from more than 100 countries. The IASLC 17<sup>th</sup> WCLC will take place in Vienna, Austria Dec. 4-7, 2016. For more information on the IASLC 17<sup>th</sup> WCLC, visit: <http://wclc2016.iaslc.org/>.

**About the WCLC:**

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 6,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. Organized under the theme of "Together Against Lung Cancer," the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit <http://wclc2016.iaslc.org/>.

**About the IASLC:**

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit [www.iaslc.org](http://www.iaslc.org) for more information.

###

